Trending Aesthetic Treatments: What Patients Are Asking For

Skinvive by Juvederm received FDA approval in 2026 for horizontal neck lines and neck appearance—a category that had no dedicated injectable until now. This is not a filler in the traditional sense; it's a smooth, low-viscosity hyaluronic acid formulation designed for superficial placement and hydration rather than volume replacement. The clinical signal is real: neck skin is thin, mobile, and prone to crepey texture, and patients have been asking for non-surgical options for years. The market opportunity is significant because neck treatment was historically bundled into facelift or filler-refresh appointments; now it's a standalone service line. Pricing and bundling: practices are positioning Skinvive as a premium add-on to chin/jawline filler or as a standalone series (often 2–3 syringes per session). The per-syringe economics are identical to standard Juvederm, so margin depends on your Allergan rebate tier (Alle program) and whether you're capturing incremental revenue or cannibalizing existing filler appointments. Patient psychology: neck concerns are often age-related insecurity that patients don't volunteer until asked directly. Training your injectors to assess and offer neck treatment—and your front desk to mention it—is as important as the product itself.

Restylane Contour earned FDA approval for temple hollowing in 2026, marking the first filler cleared specifically for this indication. Temple volume loss is clinically distinct from midface aging: it's a localized, progressive deflation that creates a gaunt appearance and paradoxically ages the entire face. Patients seeking temple correction were previously offered off-label midface fillers or biostimulators, which work but lack indication-specific data. The approval signals that Galderma (and the market) recognize temples as a distinct anatomical zone worth treating. Clinical and economic reality: temple hollowing is common in patients over 50 and in those with significant weight loss—including GLP-1 users, a growing demographic. One syringe of Contour typically addresses both temples. Because it's a targeted, high-skill procedure, it commands premium pricing and differentiates your practice from high-volume competitors. Competitive positioning: this is a Galderma play, so it ties into your Restylane ecosystem. If you're already a Galderma house, adding Contour is operationally simple. If you're Allergan-dominant, the decision is whether to diversify your filler portfolio or stay loyal to your rebate structure.

RHA Dynamic Volume (Revance) received FDA clearance for midface augmentation and age-related volume loss in 2026. RHA is a hyaluronic acid filler with a unique rheology: it's designed to move with facial expression rather than resist it, which theoretically reduces the "frozen" appearance some patients report with traditional fillers. The midface is the highest-volume treatment zone in aesthetic practice, so any new player with a credible clinical story gains immediate attention. Why it matters: RHA competes directly with Juvederm Voluma and Restylane Lyft in the premium midface segment. Revance's pitch is that RHA feels more natural because it accommodates dynamic movement. Whether this translates to measurable patient preference is still being tested in the market, but early adopters report strong patient satisfaction. Economics and risk: RHA pricing is comparable to other premium fillers, so margin is driven by volume and rebate tier. The risk is adoption friction—practices already have established midface protocols, and switching requires provider retraining and patient education. The upside is differentiation: if your injectors master RHA's specific placement and your patients notice the difference, you've created a defensible service.

Boey (trenibotulinumtoxin E) is a rapid-onset, short-duration neuromodulator approved by Health Canada in 2026 for glabellar lines. It is not yet FDA-approved in the U.S., but it represents a meaningful category innovation: onset in 24–48 hours (versus 3–7 days for botulinum toxin A) and duration of 8–10 weeks (versus 12–14 weeks). For U.S. practices, Boey is a watch-and-wait story, but the regulatory precedent matters. If and when Boey reaches the U.S. market, it will appeal to patients who want faster results and those who prefer shorter commitment intervals. Strategic implication: the neuromodulator market is mature and dominated by Allergan (Botox, Dysport), Galderma (Xeomin), and Evolus (Jeuveau). A new entrant with a genuine clinical advantage—faster onset—could capture share, especially among younger patients and those seeking "event" treatments. For practice owners, this signals that the toxin category is not static; differentiation is possible, and staying informed about new formulations is part of competitive positioning.

The aesthetic industry has confirmed that GLP-1 agonists (semaglutide, tirzepatide) cause significant facial fat loss—colloquially "semaglutide face." This is not a treatment trend but a demand catalyst. Patients losing 30–50+ pounds on GLP-1 therapy are experiencing rapid volume loss in the face, and many are seeking correction. This has created a new patient cohort: weight-loss patients who are otherwise healthy but need facial rejuvenation. Practice implications: practices in markets with high GLP-1 adoption are seeing increased demand for biostimulators (Sculptra, Radiesse) and volumizing fillers. The clinical rationale is sound—these patients need sustained volume restoration, not temporary filler. The business opportunity is significant because GLP-1 patients often require multiple treatment sessions and are motivated to invest in their appearance post-weight-loss. Messaging and positioning: practices that explicitly market to weight-loss patients—positioning filler and biostimulator treatments as part of a post-weight-loss rejuvenation package—are capturing this demand. This requires front-end marketing and patient education, not just clinical capability.

Before committing capital and training time to a new treatment, ask these questions: (1) Does it align with your patient demographic? Temple hollowing appeals to an older, higher-income demographic; RHA's "natural movement" pitch resonates with patients skeptical of injectables. (2) What is the unit economics? Compare per-syringe or per-unit cost (via Alle, Aspire, Evolus Rewards, or direct), expected patient volume, and pricing power in your market. (3) Does it require new provider skills or just product switching? Skinvive uses standard injection technique; RHA requires understanding its unique rheology; biostimulators demand patient education about delayed onset and multiple sessions. (4) What is your rebate and loyalty position? If you're deep in an Allergan or Galderma ecosystem, adding a competing product may reduce rebate tier. (5) Can you differentiate on it, or is it table-stakes? If every competitor in your market offers it, it's defensive; if you're first, it's offensive. Trending treatments are opportunities only if they fit your practice's clinical model, economics, and competitive position.